Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
Teduglutide (Gattex) vs Ziconotide (Prialt)
An educational, source-based comparison of Teduglutide (Gattex) and Ziconotide (Prialt) — how each peptide works, what it's researched for, and what to know before going deeper.
GLP-2 analog for short bowel syndrome dependent on parenteral support.
Recombinant analog of glucagon-like peptide-2 with alanine→glycine substitution at position 2, resisting DPP-IV degradation; promotes intestinal mucosal growth, villus height, and absorptive capacity.
- Short bowel syndrome with intestinal failure
- Reduction of parenteral nutrition dependence
- • FDA-approved.
- • Colorectal polyp surveillance required.
- • Risk of intestinal obstruction and biliary/pancreatic disease.
Synthetic ω-conopeptide for severe chronic pain via intrathecal infusion.
Synthetic version of ω-conotoxin MVIIA from cone snail Conus magus; selectively blocks N-type voltage-gated calcium channels on primary afferent nerve terminals in the spinal dorsal horn, inhibiting nociceptive neurotransmitter release.
- Severe chronic pain refractory to systemic analgesics, intrathecal morphine
- • FDA-approved.
- • Black-box warning for severe psychiatric and neurologic effects.
- • Contraindicated in history of psychosis.
Teduglutide (Gattex) vs Ziconotide (Prialt) — Key differences
- Class: Teduglutide (Gattex) is classified as GLP-2 Analog · Gastrointestinal, while Ziconotide (Prialt) is N-type Calcium Channel Blocker · Analgesic.
- Primary research focus: Teduglutide (Gattex) — short bowel syndrome with intestinal failure; Ziconotide (Prialt) — severe chronic pain refractory to systemic analgesics, intrathecal morphine.
- Tag: FDA-Approved · GI vs FDA-Approved · Pain.